EUCTR2015-005419-33-DE进行中（未招募）1 期
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,313
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients aged 18 to 55 years (inclusive) at screening
- •Diagnosis of MS according to the 2010 Revised McDonald criteria
- •Relapsing form of MS: relapsing-remitting course (RRMS), or secondary progressive course with disease activity (relapsing SPMS)
- •Disability status at Screening with an EDSS score of 0 to 5.5 (inclusive)
- •At least 1 documented relapse during the previous 1 year OR at least 2 documented relapses during the previous 2 years OR a positive GdE MRI scan during the year prior to and including screening.
- •Neurologically stable within 1 month prior to randomization
- •Please see protocol for complete detailed list of inclusion criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1313
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with primary progressive MS or SPMS without disease activity
- •Disease duration of more than 10 years in patients with EDSS score of 2 or less
- •Pregnant or nursing (lactating) women
- •Women of child-bearing potential
- •Patients with an active chronic disease
- •Patients with active systemic infections, or history of or known presence of recurrent or chronic infection
- •Have received any live or live-attenuated vaccines within 2 months prior to randomization
- •Have been treated with medications as specified within the timeframes specified (e.g. ofatumumab, rituximab, ocrelizumab, alemtuzumab, natalizumab, cyclophosphamide, teriflunomide, etc)
- •Any other disease or condition which could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.
- •Please see protocol for complete detailed list of exclusion criteria
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinibMedDRA version: 27.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2020-005929-89-PLovartis Pharma AG800
进行中（未招募）
1 期
Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2015-005419-33-HUovartis Pharma Services AG1,313
未知
3 期
A randomized, double-blind, double-dummy, parallel group, active controlled multi-center clinical trial to evaluate the additional efficacy and safety of Olmesartan Medoxomil/Amlodipine 20/5 mg in Chinese patients with mild or moderate essential hypertension who failed to achieve their goal with Olmesartan Medoxomil 20mg monotherapyEssential HypertensionJPRN-jRCT2080221543Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.252
进行中（未招募）
1 期
Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2015-005418-31-HRovartis Pharma Services AG900
进行中（未招募）
1 期
Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosismultiple sclerosisMedDRA version: 19.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005418-31-GRovartis Pharma AG900